The following athletes earned All-Knox Morrow Athletic Conference honors for 2024-25 this winter: Bowler of the Year: Pink Payne, Fredericktown. Coach of the Year: Russ Montgomery, Northmor.

The following wrestlers earned All-Knox Morrow Athletic Conference honors for the 2024-25 season: Wrestler of the Year: Quinten Harrison, Elgin. First team: Rocco Castricone Mount Gilead; Cory ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

Gilead (GILD) Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $130 from $123 and keeps an Overweight rating on the shares. Following recent physician checks and a “st ...

Partly cloudy with a high of 48 °F (8.9 °C). Winds from SW to WSW at 14 to 23 mph (22.5 to 37 kph). Night - Clear. Winds from WSW to SW at 6 to 19 mph (9.7 to 30.6 kph). The overnight low will ...

Once-Daily Orals and In-Depth Look at Adolescent Pharmacokinetic, Safety and Efficacy Data – "Gilead is continuing to innovate in our work to develop additional person-centered long-acting ...

FOSTER CITY, Calif., March 12, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...

Gilead Sciences has declared a quarterly dividend to stockholders on record at the close of business on March 14, 2025. (Reuters) Gilead Sciences, with a market capitalization of $143.8 billion ...

--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...